BioAtla, Inc. Common Stock (BCAB)

Price$3.53

Growth ScoreF

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-109.15%

Price vs S&P 500 (4W)-12.93%

VGM Score13.94

Market Capitalization$6.51M

All Metrics

Book Value / Share (Quarterly)$0.01

P/TBV (Annual)0.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)100.00%

Cash Flow / Share (Quarterly)$-22.40

Price vs S&P 500 (YTD)-97.09%

Net Profit Margin (TTM)-489.20%

EPS (TTM)$-37.60

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-37.60

Revenue Growth (5Y)-17.40%

EPS (Annual)$-50.66

ROI (Annual)-489.14%

Net Profit Margin (5Y Avg)-10136.95%

Cash / Share (Quarterly)$1.18

ROA (Last FY)-431.06%

Revenue Growth TTM (YoY)-81.82%

EBITD / Share (TTM)$-35.50

ROE (5Y Avg)-157.05%

Operating Margin (TTM)-483.05%

Cash Flow / Share (Annual)$-37.98

P/B Ratio11.90x

P/B Ratio (Quarterly)37.03x

Net Income / Employee (Annual)$-1,453,800

Net Interest Coverage (TTM)-11.49x

ROA (TTM)-233.57%

EPS Incl Extra (Annual)$-50.66

Current Ratio (Annual)0.37x

Quick Ratio (Quarterly)0.09x

3-Month Avg Trading Volume0.05M

52-Week Price Return-79.90%

Revenue / Employee (TTM)$48,800

Tangible BV / Share (Quarterly)$1.98

P/S Ratio (Annual)3.26x

Asset Turnover (Annual)0.14x

52-Week High$71.50

Operating Margin (5Y Avg)-10034.24%

EPS Excl Extra (Annual)$-50.66

26-Week Price Return-93.22%

Quick Ratio (Annual)0.32x

13-Week Price Return-66.89%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.15x

Enterprise Value$4.55M

Revenue / Share Growth (5Y)60.02%

Asset Turnover (TTM)0.14x

Revenue / Employee (Annual)$48,800

Pretax Margin (Annual)-2980.35%

Cash / Share (Annual)$5.61

3-Month Return Std Dev130.70%

Net Income / Employee (TTM)$-1,079,800

ROE (Last FY)-489.14%

Net Interest Coverage (Annual)-15.82x

EPS Basic Excl Extra (Annual)$-50.66

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-37.60

ROI (TTM)-235.89%

P/S Ratio (TTM)3.26x

Pretax Margin (5Y Avg)-10137.22%

Revenue / Share (Annual)$1.70

Tangible BV / Share (Annual)$3.79

Price vs S&P 500 (52W)-108.10%

Year-to-Date Return-86.15%

5-Day Price Return6.50%

EPS Normalized (Annual)$-50.66

ROA (5Y Avg)-150.40%

Net Profit Margin (Annual)-2980.35%

Month-to-Date Return-6.65%

Cash Flow / Share (TTM)$-2.64

EBITD / Share (Annual)$-50.43

Operating Margin (Annual)-2985.55%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-157.03%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-37.60

P/TBV (Quarterly)0.80x

P/B Ratio (Annual)2.40x

Pretax Margin (TTM)-489.20%

Book Value / Share (Annual)$12.28

Price vs S&P 500 (13W)-76.64%

Beta0.78x

Revenue / Share (TTM)$1.67

ROE (TTM)-235.89%

52-Week Low$3.26

gGradeF

mGradeF

vgmGradeF

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.29

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
BCABBioAtla, Inc. Common Stock	—	F	F	$3.53
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

BioAtla Inc is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for solid tumor cancers. The company's pipeline includes multiple programs featuring designed antibodies and bispecific antibodies, with lead candidates mecbotamab vedotin, ozuriftamab vedotin, and evalstotug in development, along with a Phase 1 trial for BA3182, a bispecific antibody targeting EpCAM and CD3. Its focus on precision-engineered antibodies aims to address unmet needs in oncology with potentially improved specificity and tolerability compared to conventional approaches.